

Synthesis and new skin-relevant properties of the salicylic acid ester of bakuchiol

Geovani Quijas¹, Łukasz P. Haliński², Katarzyna Gobis³, Ryszard Bojanowski¹, Krzysztof Bojanowski^{1*}

¹Sunny BioDiscovery, Inc. 972 East Main St. Santa Paula, CA, USA, tel. 805-229-7580;

²Faculty of Chemistry, Department of Environmental Analysis, University of Gdańsk; ul. Wita Stwosza 63, 80-308 Gdańsk;

³Department of Organic Chemistry, Medical University of Gdańsk, 107 Gen. Hallera Ave., 80-416 Gdańsk, Poland;

* Corresponding author; e-mail: kbojanowski@sunnybiodiscovery.com

Abstract

Bakusylan (bakuchiol salicylate) is a bipartite compound obtained by merging two skin-active entities with complementary bioactivities - bakuchiol and salicylic acid - for the purpose of generating a new class of functional retinoids with enhanced skin benefits. Here, we describe its preparation process and report that pure bakusylan exhibits potential for an improved permeation through the stratum corneum, enhances type IV collagen gene expression in organotypic skin substitutes containing both epidermal and dermal layers, and upregulates this protein in adult human dermal fibroblast cultures. The mechanism of action underlying these effects appears to involve the components of the IP3K/Akt signaling pathway selectively implicated in the maintenance of skin integrity, further underlying the suitability of this ester for skin care applications requiring enhanced cutaneous permeation, targeting the dermal-epidermal junction.




Figure S1. Photographic documentation of the starting material (bakuchiol 75% pure; left) and the purified product (98% purified bakuchiol, right).

Supplemental Material





Figure S2. Gas chromatograms from GC-MS analysis of purified bakuchiol (a), and bakusylan (b), as their TMSi derivatives. Inserts: mass spectra of substances in peaks 1 (bakuchiol) and 2 (bakusylan); (c): NMR spectrum of bakusylan; ^1H NMR (200 MHz, CDCl_3): 1.23 (s, 3H, CH_3), 1.24-1.27 (m, 2H, CH_2), 1.60 (s, 3H, CH_3), 1.70 (s, 3H, CH_3), 1.98 (q, 2H, CH_2 , $J = 8$ Hz), 5.00-5.13 (m, 3H, 3CH), 5.84-5.98 (m, 1H, CH), 6.20 (d, 1H, CH, $J = 14$ Hz), 6.37 (d, 1H, CH $J = 16$ Hz), 6.94-7.07 (m, 2H, ArH), 7.15 (d, 2H, ArH, $J = 9$ Hz), 7.44 (d, 2H, ArH, $J = 9$ Hz), 7.51-7.55 (m, 1H, ArH), 8.08 (dd, 1H, ArH, $J_1 = 6$ Hz, $J_2 = 2$ H), 10.53 (br s, 1H, OH + D_2O exchangeable) ppm.





Figure S3. Photographic documentation of the residual bakuchiol (left) and bakusylan (right) after 2h incubation on top of Strat M membrane. Unlike bakuchiol, bakusylan appears to be mostly absorbed by the membrane and thus not readily visible. This agrees with its higher hydrophobicity, and thus, presumably, better ability to blend with lipids, such as in *stratum corneum*, compared to bakuchiol.

Table I. Intramembrane permeation of bakusylan and bakuchiol 2h after topical application on Strat M membrane.		
Substance	Permeation (% of the topically deposited substance)	P value
bakuchiol	4.1	1.000
bakusylan	17	0.018 (vs. bakuchiol)

Supplemental Material


Figure S4. HPLC chromatograms at peak (256nm) and non-peak (325nm) wavelength of intra-membrane - permeated fractions of bakuchiol (A) and bakusylan (B) applied on top of Strat M membranes for 2h.



ECM

CHAD	COL1A2	LAMC2	LAMB4
COL4A3	COMP	RELN	LAMC3
COL4A5	FN1	SPP1	TNN
COL2A1	IBSP	THBS1	COL6A5
COL6A1	LAMA1	THBS2	TNXB
COL4A1	LAMA2	THBS3	COL4A6
COL4A2	LAMA3	THBS4	COL9A1
COL4A4	LAMA4	TNC	COL9A2
COL6A3	LAMA5	TNR	COL9A3
COL6A6	LAMB1	VTN	
COL6A2	LAMB2	VWF	
COL1A1	LAMB3	LAMC1	

a



b

Figure S5. ECM components of the PI3K/Akt signal transduction pathway (WikiPathways). Green and red shaded are genes respectively down- or upregulated by bakusylan in the reconstituted human epidermal tissues, as determined by RNA-seq (darker the color, stronger the modulation). [FC/p values] for the modulated genes: COL4A3: [1.6/0.047]; COL6A2: [2.1/0.038]; COL6A3: [2.1/0.021]; THBS2: [1.8/0.014]; THBS3: [-2.1/0.032]; TNC: [4.3/0.0193]; LAMB2: [1.5/0.032]; LAMC1: [1.5/0.049]; **B**: Dose-dependent upregulation of type IV collagen output in the aHDF-conditioned medium (standardized to the overall cellular metabolism). The upregulation by 5µg/ml bakusylan is statistically significant vs. water (solvent) control (132%; p=0.004). Bars represent standard errors of the mean (SEM).